{
    "title": "To amend the Federal Food, Drug, and Cosmetic Act with respect to drug and device advertising, and for other purposes.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Responsibility in Drug and Device \nAdvertising Act of 2008''.\n\nSEC. 2. DIRECT-TO-CONSUMER DRUG OR DEVICE ADVERTISING.\n\n    (a) In General.--The Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 301 et seq.) is amended--\n            (1) in section 301, by adding at the end the following:\n    ``(oo) The conduct of direct-to-consumer advertising of a drug or \ndevice in violation of section 503C.''; and\n            (2) in chapter V, by inserting after section 503B the \n        following:\n\n``SEC. 503C. DIRECT-TO-CONSUMER DRUG OR DEVICE ADVERTISING.\n\n    ``(a) Prohibitions.--\n            ``(1) First three years.--\n                    ``(A) In general.--Subject to subparagraph (B), no \n                person shall conduct direct-to-consumer advertising \n                of--\n                            ``(i) a drug for which an application is \n                        submitted under section 505(b) before the end \n                        of the 3-year period beginning on the date of \n                        the approval of such application; or\n                            ``(ii) a class II or class III device for \n                        which a premarket notification is submitted \n                        under section 510(k) or a class III device for \n                        which a premarket approval is sought under \n                        section 515, before the end of the 3-year \n                        period beginning on the date of the \n                        notification or approval, respectively.\n                    ``(B) Waiver.--The Secretary may waive the \n                application of subparagraph (A) to a drug or device \n                during the third year of the 3-year period described in \n                such subparagraph if--\n                            ``(i) the sponsor of the drug or device \n                        submits an application to the Secretary \n                        pursuant to subparagraph (C); and\n                            ``(ii) the Secretary, after considering the \n                        application and any accompanying materials, \n                        determines that direct-to-consumer advertising \n                        of the drug or device would have an affirmative \n                        value to public health.\n                    ``(C) Application for waiver.--To seek a waiver \n                under subparagraph (B), the sponsor of a drug or device \n                shall submit an application to the Secretary at such \n                time, in such manner, and containing such information \n                as the Secretary may require.\n            ``(2) Subsequent years.--\n                    ``(A) Extension of prohibition.--The Secretary may \n                prohibit direct-to-consumer advertising of a drug or a \n                class II or class III device during the period \n                beginning at the end of the 3-year period described in \n                paragraph (1)(A) if the Secretary determines that the \n                drug or device has significant adverse health effects \n                based on post-approval studies, risk-benefit analyses, \n                adverse event reports, the scientific literature, any \n                clinical or observational studies, or any other \n                appropriate resource.\n                    ``(B) Fair balance of benefits and risks for drugs \n                and devices for permitted dtc advertising.--Any direct-\n                to-consumer advertising of a drug or a class II or \n                class III device permitted under this section shall \n                include a fair balance, as supported by the evidence, \n                of the benefits and the risks associated with the drug \n                or device.\n    ``(b) Regulations.--Not later than 1 year after the date of the \nenactment of this section, the Secretary shall revise the regulations \npromulgated under this Act governing advertisements of drugs and \ndevices to the extent necessary to implement this section.\n    ``(c) Rule of Construction.--This section shall not be construed to \ndiminish the authority of the Secretary to prohibit or regulate direct-\nto-consumer advertising of drugs or devices under other provisions of \nlaw.''.\n    (b) Effective Date.--The amendments made by subsection (a) apply \nonly with respect to a drug for which an application is approved under \nsection 505(b) of the Federal Food, Drug, and Cosmetic Act, a class II \nor class III device for which a notification is submitted under section \n510(k) of such Act, or a class III device for which an application is \napproved under section 515 of such Act, on or after the date that is 1 \nyear before the date of the enactment of this Act.\n\nSEC. 3. PROMINENT DISPLAY OF INFORMATION IN ADVERTISING ON SIDE \n              EFFECTS, CONTRAINDICATIONS, AND EFFECTIVENESS.\n\n    (a) Requirement for Drugs.--\n            (1) In general.--Subparagraph (3) of section 502(n) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(n)) is \n        amended--\n                    (A) by striking ``such other information'' and all \n                that follows through ``which shall be issued by'' and \n                inserting ``such other information in brief summary \n                relating to side effects, contraindications, and \n                effectiveness as shall be required in regulations which \n                shall require such information to be prominently \n                displayed in terms of font size and location and shall \n                be issued by'';\n                    (B) by striking ``in the case of published direct-\n                to-consumer advertisements'' and inserting ``in the \n                case of direct-to-consumer advertisements (including an \n                advertisement that accompanies video programming \n                delivered by television broadcasting or by a \n                multichannel video programming distributor (as defined \n                in section 602 of the Communications Act of 1934))''; \n                and\n                    (C) by striking ``published after the effective \n                date'' and inserting ``disseminated after the effective \n                date''.\n            (2) Discontinuance of study.--The Secretary of Health and \n        Human Services shall discontinue the study required by section \n        906(b) of the Food and Drug Administration Amendments Act of \n        2007 (Public Law 110-85).\n    (b) Application of Similar Rules for Devices.--The first sentence \nof section 502(r) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 352(r)) is amended--\n            (1) by striking ``(1) a true statement'' and inserting ``a \n        true statement (1)'';\n            (2) by striking ``a brief statement''; and\n            (3) by inserting before the period at the end the \n        following: ``, and in the case of direct-to-consumer \n        advertisements (including an advertisement that accompanies \n        video programming delivered by television broadcasting or by a \n        multichannel video programming distributor (as defined in \n        section 602 of the Communications Act of 1934)) the following \n        statement printed in conspicuous text: `You are encouraged to \n        report negative side effects of medical devices to the FDA. \n        Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.'''.\n    (c) Effective Date.--The amendments made by this section apply with \nrespect to any advertisement or other descriptive printed matter that \nis issued or caused to be issued on or after the date that is 90 days \nafter the date of the enactment of this Act. Not later than 90 days \nafter the date of the enactment of this Act, the Secretary shall revise \nany regulations promulgated pursuant to subsections (n) and (r) of \nsection 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) \nto the extent necessary to implement this section.\n\nSEC. 4. CIVIL PENALTY.\n\n    Subsection (g) of section 303 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 333) is amended to read as follows:\n    ``(g) Drug or Device Advertising and Promotion.--\n            ``(1) Civil penalty.--\n                    ``(A) In general.--Any manufacturer, packer, or \n                distributor of a drug or device who violates section \n                505(n), section 503C, or any other requirement of this \n                Act relating to the advertising or promotion of the \n                drug or device shall be subject to a civil penalty in \n                an amount not to exceed--\n                            ``(i) in the case of the first such \n                        violation by the manufacturer, packer, or \n                        distributor relating to the drug or device, \n                        $1,000,000; and\n                            ``(ii) in the case of each subsequent \n                        violation by the manufacturer, packer, or \n                        distributor relating to the drug or device, an \n                        amount that is twice the amount of the maximum \n                        civil penalty applicable under this \n                        subparagraph to the previous violation.\n                    ``(B) Procedure.--Paragraphs (3) through (5) of \n                subsection (f) shall apply with respect to a civil \n                penalty under subparagraph (A) to the same extent and \n                in the same manner as those paragraphs apply with \n                respect to a civil penalty under paragraph (1), (2), \n                (3), or (4) of subsection (f).\n            ``(2) Distribution of materials.--If the Secretary finds \n        that a person committed a violation described in paragraph \n        (1)(A), the Secretary may order the person to distribute \n        materials in the same markets in which the violative \n        advertisement or promotional material was distributed in a \n        manner designed to notify the public and the medical community \n        of the violation and to provide corrective information.\n            ``(3) Separate offense.--For purposes of imposing a civil \n        penalty under this subsection, each violation described in \n        paragraph (1)(A), including each distribution of a direct-to-\n        consumer advertisement in violation of section 503C, shall \n        constitute a separate offense.\n            ``(4) Relation to other penalties.--A civil penalty under \n        paragraph (1) and an order under paragraph (2) shall be in \n        addition to any other penalty applicable under this Act or \n        other law to the violation involved.''.\n\nSEC. 5. PUBLIC EDUCATION CAMPAIGN ON RISKS OF CERTAIN DRUGS AND \n              DEVICES.\n\n    The Secretary of Health and Human Services shall conduct an \neducation campaign to increase public awareness of risks that, for some \npatients, may outweigh the benefits of using a particular drug or \ndevice, whether such risks are known at the time of the approval of the \ndrug or device or become known after the approval of the drug or \ndevice.\n\nSEC. 6. ADDITIONAL FUNDING FOR REGULATION OF DIRECT-TO-CONSUMER DRUG \n              AND DEVICE ADVERTISING.\n\n    There are authorized to be appropriated to the Food and Drug \nAdministration such sums as may be necessary for each of fiscal years \n2009 and 2010 for the purpose of regulating direct-to-consumer drug and \ndevice advertisements, including by carrying out the amendments made by \nsection 2. The authorization of appropriations in the preceding \nsentence is in addition to any other authorization of appropriations \nfor such purpose."
}